Clinical Trial Update: A Proof-of-principle Study of Oral Treatment of Non-alcoholic Steatohepatitis With a Novel PDE4 Inhibitor ASP9831 [Phase 2]

View source ↗

Summary

A Phase 2 proof-of-principle trial evaluating the PDE4 inhibitor ASP9831 for non-alcoholic steatohepatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Steatohepatitis

Drugs mentioned

• ASP9831

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Non-Alcoholic Steatohepatitis | Phase 2 | Status: COMPLETED